Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Market Cap | $1 | $3 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $2 | $4 | $2 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$1 | -$0 | -$2 |
| % Margin | – | – | – | – |
| Net Income | -$1 | $1 | -$0 | -$2 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.024 | 0.06 | -0.03 | -0.13 |
| % Growth | -140% | 298% | 76.8% | – |
| Operating Cash Flow | -$1 | -$0 | -$0 | -$1 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$0 | -$0 | -$1 |